RPID · XBRL financial data

Rapid Micro Biosystems financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RPID's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	23,232	17,133	22,519	28,051	33,587
Research and development	9,781	12,866	12,820	14,597	13,603
General and administrative	17,895	26,819	24,936	21,947	22,754
Operating income (loss)	(47,232)	(63,219)	(56,563)	(49,919)	(47,392)
Interest income	—	—	—	3,204	1,509
Interest expense	2,650	—	—	40	1,090
Other income (expense)	(808)	59	(83)	(112)	(110)
Income tax expense (benefit)	91	(576)	31	22	40
Net income (loss)	(73,524)	(60,806)	(52,467)	(46,889)	(47,123)
Earnings per share, basic USD per share	(3.94)	(1.43)	(1.22)	(1.08)	(1.05)
Earnings per share, diluted USD per share	(3.94)	(1.43)	(1.22)	(1.08)	(1.05)
Weighted average shares, basic thousands of shares	19,784	42,454	43,024	43,576	44,679
Weighted average shares, diluted thousands of shares	19,784	42,454	43,024	43,576	44,679

Fiscal years (RPID's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	178,387	27,064	24,285	16,911	20,030
Short-term investments	15,110	—	—	—	—
Marketable securities	15,110	81,584	67,768	33,821	18,266
Marketable securities, non-current	9,966	29,790	2,911	0	—
Accounts receivable	5,005	5,369	5,532	7,519	3,134
Inventory	15,671	21,187	19,961	20,200	17,593
Prepaid and other current assets	3,951	3,372	2,869	2,466	2,145
Total current assets	218,124	138,576	120,415	80,917	61,168
Property and equipment, net	11,304	13,818	12,832	11,193	8,972
Right-of-use asset	—	6,746	5,972	4,998	3,981
Total assets	241,169	190,650	143,452	98,169	74,852
Accounts payable	3,944	5,428	1,973	2,535	4,139
Accrued liabilities	10,917	8,150	9,907	7,217	8,316
Total current liabilities	18,166	19,050	18,986	17,565	18,487
Long-term debt	—	—	—	0	18,902
Lease liability, non-current	—	6,898	5,952	4,784	3,539
Total liabilities	20,189	26,481	25,463	22,817	41,646
Accumulated deficit	(315,112)	(375,918)	(428,385)	(475,274)	(522,397)
Total stockholders' equity	220,980	164,169	117,989	75,352	33,206
Total liabilities and equity	241,169	190,650	143,452	98,169	74,852

Fiscal years (RPID's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(73,524)	(60,806)	(52,467)	(46,889)	(47,123)
Stock-based compensation	1,843	4,019	4,750	3,874	4,033
Depreciation and amortization	1,529	2,837	3,105	3,362	3,252
Net cash from operating activities	(54,964)	(58,547)	(45,081)	(44,153)	(31,062)
Purchases of property and equipment	3,217	6,740	1,845	1,365	850
Net cash from investing activities	(13,289)	(93,469)	42,153	36,657	14,329
Proceeds from issuing common stock	—	—	—	0	445
Proceeds from long-term debt	—	—	—	0	20,000
Repayments of long-term debt	26,159	0	—	—	—
Net cash from financing activities	216,745	693	149	203	19,771

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Rapid Micro Biosystems	14,687	8,054	(12,702)*	not reported	1.6 quarters	Q2 FY26 10-QJun 30, 2026
Hurco Companies	52,087	47,289	3,805	6.5M	—	Q3 FY26 10-QJul 31, 2026
Owlet	30,948	33,865	(92)*	29.2M	336.4 quarters	Q2 FY26 10-QJun 30, 2026
Seer	26,075	3,102	(9,571)*	55.4M	16.0 quarters	Q2 FY26 10-QJun 30, 2026
Geospace Technologies	2,833	15,804	(10,688)*	12.9M	0.3 quarters	Q3 FY26 10-QJun 30, 2026
Intest	22,102	35,313	not reported	12.8M	—	Q2 FY26 10-QJun 30, 2026
Kewaunee Scientific	8,246	66,320	1,976	2.9M	—	Q1 FY27 10-QJul 31, 2026
908 Devices	63,019	16,074	3,171*	41.3M	—	Q2 FY26 10-QJun 30, 2026
ScanTech AI Systems	158	631	(758)*	75.6M	0.2 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.